首页 › 基金 › RA CAPITAL MANAGEMENT, L.P. › FDMT
RA CAPITAL MANAGEMENT, L.P. 对 FDMT 的持仓历史
4D MOLECULAR THERAPEUTICS IN · 医疗保健
RA CAPITAL MANAGEMENT, L.P. 在 Q3 2026 的 13F 申报中披露持有 FDMT(4D MOLECULAR THERAPEUTICS IN)5,049,779 股,市值约 US$72.3M,约占其申报组合的 0.74%,在其申报持仓中市值排名第 29 位。 RA CAPITAL MANAGEMENT, L.P. 最近 13 个申报季度中有 13 个季度披露了 FDMT 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
RA CAPITAL MANAGEMENT, L.P. 对 FDMT 的持仓演变
RA CAPITAL MANAGEMENT, L.P. 于 Q3 2023 首次披露 FDMT 持仓:4,163,211 股(约 US$53.0M)。 该持仓在 Q1 2024 达到峰值 5,051,511 股,市值约 US$160.9M。 在 13 次申报中,RA CAPITAL MANAGEMENT, L.P. 3 次增持、2 次减持、7 次保持不变。 最近一期申报(Q3 2026)显示持股 5,049,779 股、市值约 US$72.3M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 4.16M | $53.00M | 新进 |
| Q4 2023 | 4.16M | $84.35M | 持有 |
| Q1 2024 | 5.05M | $160.94M | 增持 |
| Q2 2024 | 5.10M | $107.01M | 增持 |
| Q3 2024 | 5.10M | $55.11M | 持有 |
| Q4 2024 | 4.56M | $25.42M | 减持 |
| Q1 2025 | 4.56M | $14.74M | 持有 |
| Q2 2025 | 4.56M | $16.93M | 持有 |
| Q3 2025 | 4.56M | $39.65M | 持有 |
| Q4 2025 | 5.65M | $42.40M | 增持 |
| Q1 2026 | 5.05M | $47.01M | 减持 |
| Q2 2026 | 5.05M | $67.16M | 持有 |
| Q3 2026 | 5.05M | $72.26M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 FDMT 与 13F 数据
FDMT(4D MOLECULAR THERAPEUTICS IN)属于医疗保健行业。我们追踪的基金中还有 30 只申报持有 FDMT,申报仓位最大的包括:Novo Holdings A/S (US$42.9M), BVF INC/IL (US$41.2M), Trails Edge Capital Partners, LP (US$31.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 FDMT 的基金
- Novo Holdings A/S 3.00M 股 · $42.93M · Q3 2026
- BVF INC/IL 2.88M 股 · $41.20M · Q3 2026
- Trails Edge Capital Partners, LP 2.23M 股 · $31.88M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.95M 股 · $27.90M · Q3 2026
- Evergreen Quality Fund GP, Ltd. 951.47K 股 · $13.62M · Q3 2026
- Parkman Healthcare Partners LLC 772.18K 股 · $11.05M · Q3 2026
- Catalio Capital Management, LP 684.75K 股 · $9.80M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 535.11K 股 · $7.66M · Q3 2026
- DIADEMA PARTNERS LP 421.11K 股 · $6.03M · Q3 2026
更多关于 RA CAPITAL MANAGEMENT, L.P.
常见问题
How long has RA CAPITAL MANAGEMENT, L.P. held FDMT?
RA CAPITAL MANAGEMENT, L.P. has disclosed FDMT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in FDMT?
As of Q3 2026, RA CAPITAL MANAGEMENT, L.P. holds 5.05M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $72.26M, representing 0.74% of its reported portfolio and ranking #29.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling FDMT?
In the latest 13F filing (Q3 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in FDMT. The position peaked in Q1 2024 at 5.05M shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include Novo Holdings A/S, BVF INC/IL, Trails Edge Capital Partners, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.